Stay updated on PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.

Latest updates to the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a phase II pembrolizumab study in advanced NSCLC, including its study design, eligibility criteria, outcomes, locations, and record history.SummaryDifference68%

- Check18 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces NIH website updates and says that some NIH content may use “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page previously showing a 403 Forbidden error now loads the full study record for NCT03447678, including the study overview, eligibility criteria, and locations. Additional metadata sections such as IPD sharing plans and relevant MeSH terms were added to enhance contextual information and searchability.SummaryDifference70%

Stay in the know with updates to PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.